Comprendre l’effet cumulatif du psoriasis tout au long du cycle de vie : répercussions sur la prise en charge des patients

Auteurs-es

  • Marni C. Wiseman, MD, FRCPC
  • Ashley O’Toole, MHSc, MD, FRCPC

Résumé

Le psoriasis est une maladie inflammatoire chronique de la peau qui touche environ 2 % de la population à l’échelle mondiale. Parmi les sous-types de la maladie, le psoriasis en plaques est la forme la plus courante, puisqu’elle compte pour 90 % des cas. Cette maladie est associée à de nombreuses comorbidités. Par ailleurs, elle est désormais largement reconnue comme un trouble inflammatoire à médiation immunitaire.

Biographies de l'auteur-e

Marni C. Wiseman, MD, FRCPC

La Dre Marni C. Wiseman a commencé à pratiquer la dermatologie à Winnipeg (Manitoba) en 2001. Elle enseigne à titre de professeure agrégée et chef de section en dermatologie à la Faculté de médecine de l’Université du Manitoba, la Dre Wiseman passe la plupart de ses journées à la clinique SKiNWISE DERMATOLOGY, un cabinet médical privé, où elle est directrice médicale.

Les domaines d’intérêt clinique et de recherche de la Dre Wiseman comprennent le psoriasis, la dermatite atopique, l’hidradenitis suppuritiva, l’acné et la dermatologie esthétique. Elle est chercheuse principale pour le groupe Wiseman Dermatology Research et a participé à des centaines d’essais cliniques.

La Dre Wiseman supervise et encadre fréquemment des étudiants en médecine et des résidents. Elle a publié de nombreux articles dans les domaines des maladies inflammatoires de la peau, de la photodermatose et de la malignité cutanée.

La Dre Wiseman est très active au sein de la communauté et participe notamment au programme Sun Awareness de l’Association canadienne de dermatologie. Elle est rédactrice en chef du Journal of Cutaneous Medicine and Surgery, et elle a été présidente du Skin Cancer Disease Site Group à Action Cancer Manitoba pendant 15 ans. La Dre Wiseman organise régulièrement des cliniques de dépistage du cancer de la peau dans les régions rurales du Manitoba. Elle a fait l’objet de nombreux reportages et présente régulièrement des exposés lors de réunions et de congrès nationaux et internationaux.

Ashley O’Toole, MHSc, MD, FRCPC

La Dre Ashley O’Toole est dermatologue au SKiN Centre for Dermatology de Peterborough, en Ontario, où elle est également assistante à la recherche dans le cadre de multiples essais cliniques. Elle est professeure auxiliaire à l’Université Queen’s et elle participe à la formation des étudiants en médecine et des médecins résidents. Après avoir obtenu une maîtrise en sciences de la santé et en communication comportementale à l’Université Ryerson de Toronto (Ontario), la Dre O’Toole a obtenu un diplôme en médecine de l’Université McMaster de Hamilton, en Ontario. Elle a terminé sa résidence en dermatologie à l’Université d’Ottawa, à Ottawa, en Ontario. La Dre O’Toole est l’auteure ou la co-auteure de 15 publications et participe à environ 30 essais cliniques portant sur la dermatite atopique, le psoriasis, l’alopécie, l’acné et le vitiligo.

Références

Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20:1475.

Griffiths CEM, et al. Dermatol Ther (Heidelb). 2017;7(Suppl 1):31-41.

Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis, June 2009. http://www.dermatology. ca/psoriasisguidelines. Accessed 2020 May 11.

Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. J Cutan Med Surg. 2016;20(5):375-431.

Takeshita J, et al. Psoriasis and Comorbid Diseases Part I. Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.

Dreiher J, et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol. 2008;159(4):956-60.

Ger TY, et al. Bidirectional association between psoriasis and obstructive sleep apnea: A systematic review and meta-analysis. Sci Rep. 2020;10(1):5931.

Rech J, et al. Psoriatic arthritis epidemiology, comorbid diseaseprofiles and risk factors: results from a claims database analysis. Rheumatology Advances in Practice. 2020;0:1.

Alinaghi F, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. JAAD. 2019;80:25.

Busse K, Liao W. Which psoriasis patients develop psoriatic arthritis? Psoriasis Forum. 2010;16:17.

De Oliveira M, et al. Psoriasis. Classical and emerging comorbidities. An Bras Dermatol. 2015;90:9.

Habashy J. How does psoriasis affect quality of life? Medscape. updated 2020 Nov 20. Accessed 2021 May 7. https://www.medscape.com/ answers/1943419-30274/how-does-psoriasis-affect-quality-of-life.

Pariser D, et al. Psoriasis Patient Interview Study Group. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatol Treat. 2015;1–8.

Horn EJ, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 2007;57:963.

Warren RB, et al. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164 Suppl 1:1.

Kimball AB, et al. Psoriasis: is the impairment to a patient’s life cumulative? JEADV. 2010;24:989.

Pariente B, et al. Development of the Crohn’s Disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415.

Linder MD, Kimball AB. Dermatological Diseases and Cumulative Life Course Impairment. Curr Probl Dermatol. 2015 Oct;142(4):498–499.

Strober BE. Clinical goals and barriers to effective psoriasis care. Dermatology and Therapy. 2019;9:5.

Armstrong A, et al. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. JEADV 2018;32:2200. JEADV. 2018;32:2200.

Griffiths CEM, et al. “Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.” The Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8.

Strober, Bruce, et al. “Clinical meaningfulness of complete skin clearance in psoriasis.” Journal of the American Academy of Dermatology. 2016;75(1):77-82.

Elewski BE, et al. “Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab.” Journal of dermatological treatment. 2017 Sep;28(6):492-499.

Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.

Blauvelt, Andrew, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo-and active comparator– controlled VOYAGE 1 trial. Journal of the american academy of dermatology. 2017;76(3): 405-417.

Lebwohl M, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. British Journal of Dermatology. 2010;162(1):137-146.

Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. Journal of the American Academy of Dermatology. 2017;76(1):60-69.

Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015;386(9993):541-551.

Lambert J, et al. Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and Therapy. 2021;1-11.

Poulin Y, et al. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy. Dermatol Ther. 2014;4:33.

Gladman DD, et al. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. J Rheumatol. 2017;44:519.

Armstrong A, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. JAAD 2017;76:290.

Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. JAAD. 2019;80:1029.

Amatore F, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. JEADV. 2019;33:464.

Saeki H, et al. Japanese guidance for use of biologics for psoriasis. J Dermatol. 2020;47:201.

Evolution of psoriasis endpoint use. IQVIA. 2020 July 31. Accessed 2021 May 7. at https://www.iqvia.com/ blogs/2020/07/evolution-of-psoriasis-endpoint-use

Fleming P, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. JEADV. 2015;29:1063.

Saurat JH, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558.

Marsili F, et al. J Dermatol Treat 2020; Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. J Dermatolog Treat. 2022 Feb;33(1):401-407.

Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec;173(6):1387-99.

Mahil SK et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol 2020;183:638.

Armstrong AW, et al. “Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.” Dermatology and therapy. 2021;11(3):885-905.

Mahil SK, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183:638.

Warren RB, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial. 2021;184:50.

Reich K, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831.

Blauvelt A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182:1348.

Blauvelt A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.19509. Online ahead of print.

Puig L, et al. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J Dermatol Treat. 2020;31:344.

Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840.

Reich K, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011;22:337.

https://newsroom.heart.org/news/ biologic-therapy-for-psoriasis-may-reduce-heart-disease

Stebut EV, et al. “IL-17A in psoriasis and beyond: cardiovascular and metabolic implications.” Frontiers in immunology. 2019;10:3096.

Youssef AE, et al. “Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.” Cardiovascular research. 2019;115(4):721-728.

Téléchargements

Publié

2021-06-01

Comment citer

1.
Comprendre l’effet cumulatif du psoriasis tout au long du cycle de vie : répercussions sur la prise en charge des patients. Can Dermatol Today [Internet]. 1 juin 2021 [cité 19 mars 2026];2(s06):2–15. Disponible à: https://canadiandermatologytoday.com/article/view/2-s06-wiseman-otoole

Numéro

Special Supplement, June 2021

Rubrique

Articles

Comment citer

1.
Comprendre l’effet cumulatif du psoriasis tout au long du cycle de vie : répercussions sur la prise en charge des patients. Can Dermatol Today [Internet]. 1 juin 2021 [cité 19 mars 2026];2(s06):2–15. Disponible à: https://canadiandermatologytoday.com/article/view/2-s06-wiseman-otoole

Articles les plus lus du,de la,des même-s auteur-e-s